Oxygen Biotherapeutics provides an update on communication with the FDA regarding Oxycyte Development Program

05-03-2014 Business Wire HealthComments (0)

BiotechnologyOxygen BiotherapeuticsPharmaceuticalUSA

Oxygen Biotherapeutics (NASDAQ: OXBT) announces update FDA has completed its review of the September 2013 nonclinical submission and has lifted the clinical hold on Oxycyte.

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top